Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Slides:



Advertisements
Similar presentations
D-1 Pravastatin-Aspirin Combination The Medical Need Thomas A. Pearson, M.D., Ph.D. Albert D. Kaiser Professor of Community & Preventive Medicine University.
Advertisements

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL
The Role of Anticholinergic Therapy in Moderate to Severe Asthma
An Endocrinology Clinic in Dyslipidemia
Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.
US Guidelines US Guidelines Low-risk Patients.
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
When Is Adding Aspirin to NOACs Worth the Risk?
Access to NOAC Therapy:
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Unmet Needs in the Secondary Prevention in ACS
Select Topics in Cardiovascular Medicine
Obesity and Dyslipidemia: How Would You Treat?
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum
Optimizing Outcomes in the Management of GIST
Statins and the Elderly Patient
Resistant Hypertension
Statin Selection in Special Patient Populations: A Case Challenge
New Treatments for CTEPH
Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.
Selecting NOACs for High-Risk Patients
Antiplatelet Therapy and Secondary Prevention
The Essentials for Secondary Stroke Prevention
Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
An Update on PCSK9 Inhibitors
Talking to Patients About Diabetes Management
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Treatment Options to Consider
Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.
What's New in Dyslipidemia?
Access to NOAC Therapy:
Learning Objectives Classification of VTE Goals of VTE Treatment.
Practical Considerations to Extend Treatment for VTE
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
Aspirin and Cardioprevention in 2018
Factor Xa Inhibitors in PAD
CAD/PAD in Primary Care
A Time for Change for Managing Patients With VTE Who Have Cancer
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Statins, Obesity, and Hyperlipidemia
Managing Pulmonary Embolism Posthospital Discharge
Critical Decision Points in Insomnia
Controlling Elevated Blood Pressure
LDL Cholesterol.
Proteasome Inhibitors and Patients
How to Optimize Cholesterol Management in High-Risk CV Patients
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Reducing Risk for CV Outcomes
Factor Xa Inhibitors in Coronary Artery Disease
Improving Adherence to Antiplatelet Therapy After an ACS Event
Practical Strategies for Getting Patients With Diabetes to Lipid Goal
Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum
An Unmet Need.
New Lipid-Lowering Guidelines
An Update on PCSK9 Inhibitors
AMD Therapy: Where Are We Now and Where Are We Going?
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Omega-3s vs Pure EPA in Clinical Practice
Clinical Comparisons in CTEPH
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
ESC Guideline on the Management of STEMI Recommendation for DAPT
PCSK9 Inhibitors and Real-World Evidence
Shared-Decision Making in Dyslipidemia
Translating Data From Trial to Practice
Presentation transcript:

One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient

Panelists

Program Goals

Case Study

Current Medications

Case Study (cont)

Lipid Guidelines for Patients With ASCVD Secondary Prevention

Treatment of Hypertension in Those With Known Coronary Artery Disease

Antiplatelet Therapy in Secondary Prevention

Mechanism of Action of Aspirin

What Is the Right Dose of Aspirin?

Aspirin Tolerability and Safety

Aspirin Adherence and Treatment Discontinuation

Aspirin Resistance

Diabetes: A Prothrombotic State

Primary Outcomes at 4 Years Among REACH Registry Patients

Back to Our Patient…

Other Factors That May Be Associated With Aspirin Resistance

Types of Aspirin Formulations Currently Available

Aims of DURATION Study

DURATION Study Methods

DURATION Study Results

DURATION Study Conclusion

Conclusion

Abbreviations

Abbreviations (cont)

Abbreviations (cont)